Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Although immune checkpoint blocking (ICB) therapeutic agents have significantly improved the survival for many cancer patients, the efficacy of ICB therapy for non-small cell lung cancer (NSCLC) patients remains limited. Combining ICB therapy with other strategies that is able to stimulate tumor immunogenicity or increase infiltration of T cells aroused great concern in cancer therapy.

Results: Herein, we constructed a kind of AuNP@NH-PEG-SH/PD-L1 siRNA nanoparticle complex which showed prominent photothermal therapeutic (PTT) effects triggered by NIR laser and could efficiently deliver PD-L1 siRNA into NSCLC cells (knock-down efficiency were 75.8% and 83% in HCC827 and A549 cells). During the process of photothermal stimulation, discrepancies in heat shock protein expression were observed in NSCLC cells. Knocking down PD-L1 expression in NSCLC cells such as A549 and HCC827 cells activated the co-culturing Jurkat cells and enhanced their tumor-killing effect in vitro (cell inhibition rate was 62.65% for HCC827 cells and 57.03% for A549 cells). The gold nanoparticle complexes exhibited remarkable PTT effect for the engrafted NSCLC cells in zebrafish larvas. Furthermore, the nano complexes could promote the activation of the xenografted human peripheral blood mononuclear cells (PBMCs) and enhance the killing of the NSCLC cells in the larvas.

Conclusion: It is well known that gold nanoparticle is one of the several metal nanoparticles approved for clinical trial by American FDA. This work has demonstrated the outstanding PTT and immunotherapeutic effects of gold nanoparticle complexes on NSCLC, indicating great potential in clinical regiment of lung cancers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12248239PMC
http://dx.doi.org/10.2147/IJN.S518427DOI Listing

Publication Analysis

Top Keywords

nsclc cells
24
cells
14
gold nanoparticle
12
photothermal therapeutic
8
pd-l1 sirna
8
nsclc
8
killing nsclc
8
icb therapy
8
a549 cells
8
hcc827 cells
8

Similar Publications

Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.

View Article and Find Full Text PDF

The epidermal growth factor receptor (EGFR) is a common diver gene for lung cancer (NSCLC), which leads to an increasing death rate worldwide. This study reports the design, synthesis, and biological evaluation of triazole-clubbed pyrimidine derivatives (RDa-RDm) as potential anticancer agents. Thirteen compounds were synthesized and screened against the A549 lung cancer cell line.

View Article and Find Full Text PDF

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer.

Rep Pract Oncol Radiother

August 2025

Department of Oncology and Radiotherapy, University Hospital in Pilsen, Pilsen, Czech Republic.

In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists. OMD is a kind of an "umbrella term" for a variety of clinical situations. This review focuses on the role of radiotherapy (RT) in the treatment of oligometastatic non-small cell lung cancer (OM-NSCLC).

View Article and Find Full Text PDF

Introduction: Endothelial cells play a critical role in tumor-associated vasculature formation and immune modulation, and dysregulation of transcription factors (TFs) such as Meox1 has been associated with various cancers, including non-small cell lung cancer (NSCLC). Meox1 has been implicated in promoting both tumor-promoting and immune-suppressing functions.

Methods: In this study, to systematically map TF dynamics across cancer and immune cells, we performed scRNA-seq on tumor tissues and used the SCENIC framework for regulon analysis, revealing cell-type-specific gene regulatory networks.

View Article and Find Full Text PDF

Purpose: ImmunoPET imaging of PD-L1 has emerged as a promising strategy for patient stratification and treatment response monitoring in immunotherapy. This study aimed to evaluate [Zr]Zr-DFO-Durvalumab in noninvasive imaging of PD-L1 expression in non-small cell lung cancer (NSCLC) and bladder cancer.

Materials And Methods: Durvalumab was conjugated with -SCN-Bn-DFO and labeled with [Zr]Zr-oxalate, achieving high radiochemical purity (> 99 %) and stability.

View Article and Find Full Text PDF